BEAM conditioning regimen ensures better progression-free survival compared with TEAM but not with FEAM in lymphoma patients undergoing autologous stem cell transplant-Reference-Cited by-同舟云学术

BEAM conditioning regimen ensures better progression-free survival compared with TEAM but not with FEAM in lymphoma patients undergoing autologous stem cell transplant

Published:2020-05-18 Issue:9 Volume:61 Page:2238-2241
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Marchesi Francesco¹,Capria Saveria²,Pedata Mariangela³,Terrenato Irene⁴,Ballotta Laura²,Riccardi Cira³,Papa Elena¹,Riemma Costantino²,Trisolini Silvia²,Celentano Maria³,Regazzo Giulia⁵,Ferrara Felicetto⁶,Mengarelli Andrea¹,Picardi Alessandra³

Affiliation:

1. Hematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy;

2. Division of Hematology, Department of Translational and Precision Medicine, University of Rome ‘Sapienza’, Rome, Italy;

3. Stem Cell Transplant Program of AORN Cardarelli, Naples, Italy;

4. Biostatistics and Bioinformatic Unit, Scientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy;

5. Genomic and Epigenetic Unit, Translational Research Area, IRCCS Regina Elena National Cancer Institute, Rome, Italy;

6. Hematology of AORN Cardarelli, Naples, Italy

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1765238

Reference10 articles.

1. Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review

2. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

3. Replacing carmustine by thiotepa and cyclophosphamide for autologous stem cell transplantation in Hodgkin’s and non-Hodgkin’s B-cell lymphoma

4. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study

5. Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine‐based high‐dose chemotherapy regimen

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of clinical factors impacting outcome in patients undergoing autologous hematopoietic cell transplantation after BEAM and TEAM conditioning;European Journal of Haematology;2023-10-12

2. Long-Term Results with Thiotepa-Containing Conditioning Regimens for Autologous Stem Cell Transplantation;Transplantation and Cellular Therapy;2023-08

3. Comparative Efficacy and Safety of Beam and Team Conditioning Regimens for Autologous Stem Cell Transplantation in Lymphoma Patients;Transplantation Proceedings;2023-01

4. Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma;Bone Marrow Transplantation;2022-05-10

5. High dose melphalan is an adequate preparative regimen for autologous hematopoietic stem cell transplantation in relapsed/refractory lymphoma;Hematology;2022-04-12